Clinical characteristics in patients with advanced stage at diagnosis according to the type of cytopenia: C immune versus C infiltrative
| . | C immune (n = 19) . | C infiltrative (n = 54) . | P . |
|---|---|---|---|
| Median age, y (range) | 69 (40-86) | 70 (28-90) | NS |
| Male (%) | 74 | 65 | NS |
| WBC count, ×109/L (range) | 25.9 (9.9-334) | 30.1 (2.5-454) | NS |
| Hb, ×109/L (range) | 10.5 (6-16.6) | 10 (5-15.4) | NS |
| Platelet count, ×109/L (range) | 132 (19-347) | 89.5 (10-483) | NS |
| ALC, ×109/L (range) | 15.3 (4.4-257) | 23 (1.4-444) | NS |
| BM infiltration, % (range)* | 54 (16-99) | 80 (20-100) | 04 |
| PS < 2% | 67 | 83 | NS |
| B2M > 2.5 mg/L, % | 50 | 85 | .03 |
| No. of nodal areas | NS | ||
| ≤ 2 LN areas, n | 14 | 40 | NS |
| > 2 LN areas, n | 5 | 12 | NS |
| Follow-up, y | NS | ||
| All patients, median (range) | 5 (0-13) | 3.5 (0-13) | NS |
| Alive patients, median (range) | 5.6 (0-12.8) | 4 (0-7.3) | NS |
| . | C immune (n = 19) . | C infiltrative (n = 54) . | P . |
|---|---|---|---|
| Median age, y (range) | 69 (40-86) | 70 (28-90) | NS |
| Male (%) | 74 | 65 | NS |
| WBC count, ×109/L (range) | 25.9 (9.9-334) | 30.1 (2.5-454) | NS |
| Hb, ×109/L (range) | 10.5 (6-16.6) | 10 (5-15.4) | NS |
| Platelet count, ×109/L (range) | 132 (19-347) | 89.5 (10-483) | NS |
| ALC, ×109/L (range) | 15.3 (4.4-257) | 23 (1.4-444) | NS |
| BM infiltration, % (range)* | 54 (16-99) | 80 (20-100) | 04 |
| PS < 2% | 67 | 83 | NS |
| B2M > 2.5 mg/L, % | 50 | 85 | .03 |
| No. of nodal areas | NS | ||
| ≤ 2 LN areas, n | 14 | 40 | NS |
| > 2 LN areas, n | 5 | 12 | NS |
| Follow-up, y | NS | ||
| All patients, median (range) | 5 (0-13) | 3.5 (0-13) | NS |
| Alive patients, median (range) | 5.6 (0-12.8) | 4 (0-7.3) | NS |
NS indicates not significant; WBC, white blood cell; Hb, hemoglobin; ALC, absolute lymphocyte count; BM, bone marrow; PS, performance status; LN, lymph node.
Assessed by BM aspirate or biopsy or both.